Ustekinumab for treating moderately to severely active ulcerative colitis – guidance (TA633)

Ustekinumab is recommended for moderately to severely active ulcerative colitis in adults when conventional therapy or a biologic cannot be tolerated, or the disease has responded inadequately or lost response only if an anti-TNF has failed, is not tolerated, or not suitable.

Source:

National Institute for Health and Care Excellence